Last updated on August 2018

Safety and Biomarker Study of EPI-589 in Subjects With ALS

Brief description of study

Open label study with EPI-589 and ALS subjects

Detailed Study Description

Open label with 30-day run in phase to establish baseline parameters and a 90-day withdrawal phase to determine duration of treatment response.

Clinical Study Identifier: NCT02460679

Contact Investigators or Research Sites near you

Start Over

Robert Baloh, MD, PhD

Cedar's Sinai
Los Angeles, CA United States

Robert Miller, MD

California Pacific Medical Center
San Francisco, CA United States

Kimberly Goslin, MD, PhD

Providence Brain and Spine Institute ALS Center
Portland, OR United States